Five international healthtech startups have made it to the final phase of DayOne Health 4.0. With this accelerator, DayOne, the initiative of Basel Area Business & Innovation, aims to promote solutions that focus on artificial intelligence, data and clinical development.
Group picture with winners, coaches and selection committee members of DayOne Health 4.0 (image: Mathias Mangold)
The selection committee has chosen five healthtech startups for the second and final phase of the six-month DayOne Health 4.0 accelerator programme: Briya from Israel, CliniNote from Poland, FindMeCure from Bulgaria, InSilicoTrials Technologies from Italy and machineMD from Switzerland. DayOne is an initiative of Basel Area Business & Innovation, the investment and innovation promotion agency. It is doing pioneering work for the future of healthcare.
The thematic focus of this edition of the accelerator, which began in September 2023 and ends in March 2024, is artificial intelligence (AI), data and digitally improved clinical development. It received a total of 109 applications from 35 countries. Fifteen of the applications had passed Phase 1 by mid-November. According to the jury, the five projects that have now been selected offer a strong value proposition, made significant progress in phase 1 of the programme, and are ready to engage in collaborations, particularly with biopharmaceutical companies.
Startups cover a broad spectrum
Briya offers a data platform that enables pharmaceutical companies and medical researchers to access real, anonymized patient data from hospitals. CliniNote supports medical staff with clinical documentation using AI and neuro-linguistic programming. FindMeCure helps pharma, biotech and clinical research organisations make data-driven decisions that lead to effective clinical trial strategies and faster patient recruitment.
InSilicoTrials is developing a modelling and simulation platform that predicts and evaluates the safety and efficacy of new drugs and medical products. Lastly, MachineMD is committed to the early diagnosis of neurological diseases. It uses virtual reality to assess eye movements and pupil function to improve the measurement of brain function.
